News &amp; Updates

In adults with cardiovascular‐kidney‐metabolic (CKM) syndrome, higher intake of omega‐3 polyunsaturated fatty acids (n‐3 PUFAs) has been associated with less severe CKM stage and lower mortality in new research.

Omega‐3 provides some benefit in cardiovascular‐kidney‐metabolic syndrome

GLP1-RA enhances semen quality, testosterone levels in men with metabolic disorder

The use of GLP-1 receptor agonists (RAs) is associated with improved testosterone levels and semen quality in men with metabolic issues, while maintaining gonadotropin function, reports a study.

GLP1-RA enhances semen quality, testosterone levels in men with metabolic disorder

LGBTQ+ adults face poorer quality of life, socioeconomic status

A recent study in Finland has shown that lesbian, gay, bisexual, transgender, queer, and other sexual and gender minority (LGBTQ+) individuals aged 33‒35 years have a higher likelihood of being unpartnered, higher BMI, poorer self-rated health, lower socioeconomic status, and more functional limitations than heterosexual counterparts. However, no difference is seen in physical morbidity.

LGBTQ+ adults face poorer quality of life, socioeconomic status

Successful endodontic Tx tied to cardiometabolic benefits

In a self-controlled, longitudinal cohort study on individuals with apical periodontitis (AP), successful endodontic treatment is associated with improvements in glucose tolerance and lipid profile, suggesting a potential role in alleviating cardiometabolic disease risk.

Successful endodontic Tx tied to cardiometabolic benefits

Bariatric surgery, GLP1-RAs effectively reduce fat mass in obese adults

Among adults with obesity, either bariatric surgery or glucagon-like peptide 1 receptor agonists (GLP-1 RAs), such as semaglutide or tirzepatide, led to substantial fat mass (FM) loss and moderate fat-free mass (FFM) loss, according to a recent study.

Bariatric surgery, GLP1-RAs effectively reduce fat mass in obese adults

Kidney outcomes in T2D better with SGLT2i vs GLP1-RA

27 Jan 2026 by

In adults with type 2 diabetes (T2D), treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) confers better protection against chronic and acute kidney events compared with a glucagon-like peptide-1 receptor agonist (GLP-1RA), according to a comparative effectiveness study with a target trial emulation design.

Kidney outcomes in T2D better with SGLT2i vs GLP1-RA

27 Jan 2026

Serum total antioxidant capacity, uric acid tied to obesity in children

Serum uric acid (SUA) and total antioxidant capacity (sTAC) show a positive association with obesity in children, suggests a Mexico study.

Serum total antioxidant capacity, uric acid tied to obesity in children

Berberine of little benefit in individuals with obesity and MASLD

Treatment with berberine in diabetes-free individuals with obesity and metabolic dysfunction–associated steatotic liver disease (MASLD) is safe but falls short of reducing visceral adipose tissue (VAT) and liver fat content, as reported in a study.

Berberine of little benefit in individuals with obesity and MASLD